Alnylam Pharmaceuticals (ALNY) Stock Price

Alnylam Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The main competitors of Alnylam Pharmaceuticals Inc in the market include Moderna, Inc., Ionis Pharmaceuticals, Inc., and Arbutus Biopharma Corporation.

Alnylam Pharmaceuticals Inc is a renowned biopharmaceutical company that specializes in RNA interference (RNAi) therapeutics. Founded in 2002, Alnylam has emerged as a trailblazer in the development of innovative RNAi-based treatments. The company's commitment to advancing cutting-edge science and research has propelled its success in transforming the field of RNAi therapeutics. Alnylam's extensive portfolio includes groundbreaking treatments for various diseases, utilizing its proprietary platform technology. With a strong focus on precision medicine and improving patient outcomes, Alnylam Pharmaceuticals Inc has firmly established itself as a leader in the biopharmaceutical industry.

Alnylam Pharmaceuticals Inc has achieved significant milestones since its inception. Some notable accomplishments include gaining approval from the U.S. Food and Drug Administration (FDA) for their groundbreaking RNA interference (RNAi) therapeutic, ONPATTRO®. This marked a major milestone in the field of RNAi therapeutics as it became the first-ever FDA-approved RNAi therapeutic. Furthermore, Alnylam has successfully launched and commercialized ONPATTRO® in the United States and several European countries. The company has also made advancements in its pipeline, developing potential treatments for various rare genetic diseases. Overall, Alnylam Pharmaceuticals Inc has made substantial progress and continues to drive innovation in the field of RNAi therapeutics.

Alnylam Pharmaceuticals Inc is primarily present in the United States, Europe, and the Asia-Pacific region. The company has established a strong presence in these key markets to maximize its global reach and cater to a diverse patient population. By expanding its operations internationally, Alnylam Pharmaceuticals Inc aims to ensure widespread accessibility to its innovative therapies and transformative treatments. Consequently, the company has successfully expanded its footprint across multiple countries and regions, solidifying its position as a prominent player in the global biopharmaceutical industry.

Alnylam Pharmaceuticals Inc represents values of innovation, collaboration, and patient-focused research. The company is dedicated to pioneering RNA interference (RNAi) therapeutics to treat debilitating diseases. Alnylam strives to improve patient outcomes through their robust pipeline of potential therapies. With a commitment to scientific excellence and rigorous clinical development, Alnylam aims to transform the lives of those affected by rare genetic diseases. Through strategic partnerships and an unwavering dedication to advancing the field of RNAi therapeutics, Alnylam Pharmaceuticals Inc continues to drive change in the pharmaceutical industry.

Analysts currently set an average price target of 361.73 USD for the Alnylam Pharmaceuticals stock (median: 350.00 USD), implying +140.4 % versus the latest price. The consensus is based on 38 analyst ratings.

Alnylam Pharmaceuticals Analyst Price Targets 2026

38 analysts currently rate the Alnylam Pharmaceuticals stock: 29 recommend buying, 9 holding and 0 selling. For 2026, analysts expect Alnylam Pharmaceuticals to generate revenue of 5.47 B USD and earnings per share of 6.30 USD.

Alnylam Pharmaceuticals Analyst Price Targets 2026

Converted at the current exchange rate, the Alnylam Pharmaceuticals share trades at 139.40 EUR (155.94 USD).

The Alnylam Pharmaceuticals share (ALNY) is listed on 9 stock exchanges, including: NASDAQ (ALNY), London (0HD2.L), SIX (Zürich) (DUL.SW), XETRA (DUL.DE), Frankfurt (DUL.F), München (DUL.MU), Düsseldorf (DUL.DU), Hamburg (DUL.HM).

Alnylam Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for rare and genetic diseases. The company was founded in 2002 and is based in Cambridge, Massachusetts. Alnylam is known for its groundbreaking research and development of RNA interference technology. Alnylam's business model is based on the discovery, development, and commercialization of therapies for rare and genetic diseases through the use of its proprietary RNA interference (RNAi) technology platform, which selectively silences malfunctioning genes. The company holds a leadership position in RNAi therapy and is a frontrunner in the development of RNAi therapeutics for curable diseases. The company offers products for various diseases, including polyneuropathy, hereditary ATTR amyloidosis, porphyria, and hemophilia. The company's products help prevent lasting damage from these diseases and improve patients' quality of life. Alnylam has a robust pipeline of RNAi therapeutics targeting various disease areas. The company has several brands in development, including Givosiran for the treatment of acute intermittent porphyria (AIP), Patisiran for the treatment of polyneuropathy in patients with hATTR amyloidosis, Lumasiran for the treatment of primary hyperoxaluria type B, and Fitusiran for the treatment of hemophilia. The company benefits from developing a wide range of RNAi therapeutics that can be used in different disease areas. It also has a strong intellectual property pipeline that allows for long-term protection of its technologies. Alnylam also engages in collaborations with other companies and partners. The company has formed partnerships with Sanofi Genzyme and other companies to accelerate the development and commercialization of RNAi therapeutics. In addition to its RNA interference therapies, Alnylam is also building a platform for the development of other RNA therapy candidates, including bispecific antibodies, modified mRNAs, and small interfering RNA candidates, to further harness the potential of RNA technology. Overall, Alnylam's business model is based on the research and development of RNA therapeutics for rare and genetic diseases. The company has a robust pipeline of RNAi therapeutics and plans to develop other forms of RNA therapies as well. Alnylam is a leading company in this emerging field and will continue to drive innovation in the future to help patients with curable diseases.

The expected revenue of Alnylam Pharmaceuticals is 5.47 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Alnylam Pharmaceuticals is 857.98 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Alnylam Pharmaceuticals is currently 24.77. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Alnylam Pharmaceuticals stock.

The price-to-sales ratio (P/S) of Alnylam Pharmaceuticals is currently 3.89. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Alnylam Pharmaceuticals stock.

The Eulerpool Quality Score for Alnylam Pharmaceuticals is 7/10.

The ISIN of Alnylam Pharmaceuticals is US02043Q1076. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Alnylam Pharmaceuticals is A0CBCK. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Alnylam Pharmaceuticals is ALNY. The ticker symbol is used to trade Alnylam Pharmaceuticals shares on the stock exchange.